



RSV immunisation decision aid 2026

Pregnant women



Children under 2 years of age



Eligibility for Beyfortus immunisation

Child medical risk conditions (MRC)

- Preterm birth <32 weeks gestational age
- Haemodynamically significant congenital heart disease
- Significant immunosuppression, such as from malignancy, solid organ transplant
- Haematopoietic stem cell transplant, or primary immune deficiencies
- Chronic lung disease requiring ongoing oxygen or respiratory support
- Neurological conditions that impair respiratory function
- Cystic fibrosis with severe lung disease or weight for length <10th percentile
- Trisomy 21 or another genetic condition that increases the risk of severe RSV disease.

Maternal immunosuppression

- Active leukaemia or lymphoma, or other generalised malignancy
- Received recent chemotherapy or radiotherapy
- HIV (certain people only)
- Solid organ transplant (SOT) or Haematopoietic stem cell transplant (HSCT) less than 2 years ago, or are still immunocompromised or taking immunosuppressive drugs, or have graft-versus-host disease
- Immunosuppressive therapy, including bDMARDs or tsDMARDs (biological or targeted synthetic disease-modifying anti-rheumatic drugs), or high-dose corticosteroids
- Certain autoimmune diseases, particularly if they are on highly immunosuppressive therapy
- Have congenital immunodeficiency.

Dosage information

The below 3 options each equate to 1 dose

- <5kg = 50mg
- ≥5kg and <8 months = 100mg
- ≥5 kg and ≥8months = 200mg (2x100mg pre-filled syringes).

***Note:** Regardless of receiving Beyfortus in first RSV season or born to a mother who received RSV vaccine during pregnancy. Ensure minimum interval of 6 months between Beyfortus doses.